Cardinal Health is expected to report fiscal fourth-quarter 2026 revenue of $65.15 billion and EPS of $2.42, with the stock currently trading at $236.40 against a $252.40 average analyst price target.
Investors are intensely focused on the Pharmaceutical and Specialty Solutions segment profit, estimated at $628 million, as a primary indicator of growth in specialty drugs and biosimilars.
While Cardinal Health has exceeded EPS estimates for seven consecutive quarters, recent revenue misses and tariff pressures in the Global Medical Products and Distribution segment remain key areas of concern.
Market participants are also awaiting the initial fiscal 2027 guidance to confirm if the current double-digit earnings growth trajectory is sustainable.